Genomics and the development of new diagnostics and anti-Candida drugs

M. Weig, Alistair James Petersen Brown

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Pathogenic Candida species remain a significant medical problem despite the availability of antifungal therapies. Two key issues must be addressed to improve the treatment of life-threatening systemic Candida infections. First, advanced diagnostic tools are required to facilitate the early identification of these infections, when therapeutic intervention is more likely to be effective. Second, improved antifungal therapies are needed. These therapies, which might include combinations of antifungals, need to be less toxic to the patient and more potent in killing a broader range of Candida species. Recent advances in unravelling the genomics of these species should facilitate efforts to achieve these goals. We discuss the contribution of genomics to the development of novel antifungals and new diagnostic tools.
Original languageEnglish
Pages (from-to)310-317
Number of pages8
JournalTrends in Microbiology
Volume15
Issue number7
Early online date14 Jun 2007
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Genomics
Candida
Pharmaceutical Preparations
Therapeutics
Poisons
Infection

Cite this

Genomics and the development of new diagnostics and anti-Candida drugs. / Weig, M.; Brown, Alistair James Petersen.

In: Trends in Microbiology, Vol. 15, No. 7, 07.2007, p. 310-317.

Research output: Contribution to journalArticle

Weig, M. ; Brown, Alistair James Petersen. / Genomics and the development of new diagnostics and anti-Candida drugs. In: Trends in Microbiology. 2007 ; Vol. 15, No. 7. pp. 310-317.
@article{8c4747656ff040b399ecfaf617304a5b,
title = "Genomics and the development of new diagnostics and anti-Candida drugs",
abstract = "Pathogenic Candida species remain a significant medical problem despite the availability of antifungal therapies. Two key issues must be addressed to improve the treatment of life-threatening systemic Candida infections. First, advanced diagnostic tools are required to facilitate the early identification of these infections, when therapeutic intervention is more likely to be effective. Second, improved antifungal therapies are needed. These therapies, which might include combinations of antifungals, need to be less toxic to the patient and more potent in killing a broader range of Candida species. Recent advances in unravelling the genomics of these species should facilitate efforts to achieve these goals. We discuss the contribution of genomics to the development of novel antifungals and new diagnostic tools.",
author = "M. Weig and Brown, {Alistair James Petersen}",
year = "2007",
month = "7",
doi = "10.1016/j.tim.2007.05.007",
language = "English",
volume = "15",
pages = "310--317",
journal = "Trends in Microbiology",
issn = "0966-842X",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Genomics and the development of new diagnostics and anti-Candida drugs

AU - Weig, M.

AU - Brown, Alistair James Petersen

PY - 2007/7

Y1 - 2007/7

N2 - Pathogenic Candida species remain a significant medical problem despite the availability of antifungal therapies. Two key issues must be addressed to improve the treatment of life-threatening systemic Candida infections. First, advanced diagnostic tools are required to facilitate the early identification of these infections, when therapeutic intervention is more likely to be effective. Second, improved antifungal therapies are needed. These therapies, which might include combinations of antifungals, need to be less toxic to the patient and more potent in killing a broader range of Candida species. Recent advances in unravelling the genomics of these species should facilitate efforts to achieve these goals. We discuss the contribution of genomics to the development of novel antifungals and new diagnostic tools.

AB - Pathogenic Candida species remain a significant medical problem despite the availability of antifungal therapies. Two key issues must be addressed to improve the treatment of life-threatening systemic Candida infections. First, advanced diagnostic tools are required to facilitate the early identification of these infections, when therapeutic intervention is more likely to be effective. Second, improved antifungal therapies are needed. These therapies, which might include combinations of antifungals, need to be less toxic to the patient and more potent in killing a broader range of Candida species. Recent advances in unravelling the genomics of these species should facilitate efforts to achieve these goals. We discuss the contribution of genomics to the development of novel antifungals and new diagnostic tools.

U2 - 10.1016/j.tim.2007.05.007

DO - 10.1016/j.tim.2007.05.007

M3 - Article

VL - 15

SP - 310

EP - 317

JO - Trends in Microbiology

JF - Trends in Microbiology

SN - 0966-842X

IS - 7

ER -